Related Experiment Videos
Stat1 implication in the immune response to superantigens in vivo
R Gimeno1, J Codony-Servat, M Plana
1Department of Immunology, Sant Pau Hospital, Autonomous University of Barcelona, Spain.
Journal of Immunology (Baltimore, Md. : 1950)
|February 15, 1996
Summary
Superantigen treatment activates STAT1 (Signal Transducer and Activator of Transcription 1) DNA-binding complexes in mice, implicating interferon-gamma in the immune response. Protein levels increase, but DNA binding fluctuates with repeated superantigen exposure.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Superantigens are potent immune activators.
- STAT1 is a key transcription factor in immune signaling.
Purpose of the Study:
- To investigate STAT1 activation and protein level changes following in vivo superantigen treatment.
- To elucidate the role of interferon-gamma in superantigen-induced immune responses.
Main Methods:
- In vivo treatment of mice with staphylococcal enterotoxin B (SEB).
- Analysis of STAT1-DNA binding complexes in splenocytes using electrophoretic mobility shift assays.
- Western blot analysis to quantify STAT1 protein isoforms.
- Inhibition studies using cyclosporin A and antibodies against IFN-gamma.
Main Results:
- SEB treatment induced a STAT1-DNA binding complex in mouse splenocytes with characteristics similar to IFN-gamma-induced complexes.
- Activation of this complex was inhibited by cyclosporin A and reduced by anti-IFN-gamma antibodies.
- SEB treatment led to increased STAT1 protein isoforms (STAT91, STAT84) at 24 hours post-injection.
- STAT1-DNA binding decreased at 24 hours but recovered upon secondary SEB injection.
Conclusions:
- Interferon-gamma is implicated in the in vivo immune response to superantigens.
- STAT1 activation and protein expression dynamics are crucial in understanding superantigen-mediated immune events.
- Analysis of transcription factors provides insight into molecular mechanisms of immune responses.